A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-40202 in Healthy Subjects
Latest Information Update: 15 Apr 2025
At a glance
- Drugs BW 40202 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Therapeutic Use
- Sponsors Argo Biopharma
- 15 Apr 2025 New trial record